Fortress Biotech
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 186
- Market Cap
- $46.7M
- Introduction
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Journey Medical Corporation Announces DFD-29 Data
DFD-29, a modified-release formulation by Journey Medical, shows higher dermal concentration than doxycycline, potentially impacting rosacea treatment. Rosacea affects millions, impacting self-esteem and social interactions. Journey Medical markets dermatological treatments, focusing on FDA-approved products.
Journey Medical Corporation Announces U.S. FDA Acceptance of NDA for DFD-29 Targeting Rosacea Treatment
Journey Medical Corporation announced FDA acceptance of its NDA for DFD-29, targeting rosacea treatment, with a PDUFA goal date of November 4, 2024. DFD-29, supported by positive Phase 3 trial data, aims to treat both inflammatory lesions and erythema, potentially becoming a preferred oral medication for rosacea.
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Journey Medical Corporation announced FDA acceptance of its NDA for DFD-29, targeting rosacea treatment, with a PDUFA goal date of November 4, 2024. DFD-29 showed superiority in Phase 3 trials over current treatments, aiming to address both inflammatory lesions and erythema in rosacea patients.
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Journey Medical Corporation submitted an NDA to the FDA for DFD-29, a potential best-in-class oral treatment for rosacea's inflammatory lesions and erythema, supported by positive Phase 3 clinical data. DFD-29 showed superiority over current treatments and placebo in trials, aiming to improve the treatment paradigm for rosacea patients.
Priority review granted for CUTX-101
CUTX-101, a treatment for Menkes disease, received FDA Priority Review with a PDUFA target action date of June 30, 2025. Cyprium Therapeutics, under Fortress Biotech, may receive royalties and up to $129M in milestones. CUTX-101 showed significant survival improvement in trials, potentially becoming the first FDA-approved Menkes disease treatment.
© Copyright 2025. All Rights Reserved by MedPath